photobyphm / Shutterstock.com
American pharmaceutical company Merck & Co. has secured a victory against its rival Pfizer in an inter partes review of a patent concerning Prevnar 13, the biggest-selling vaccine in the world.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck & Co., Pfizer, Prevnar 13, vaccine, pneumonia, patent invalidation, Patent Trial and Appeal Board, prior art
